Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I multiple ascending dose (MAD) study of ASC47 in combination with tirzepatide or semaglutide in patients with obesity

Next Previous
Trial Profile

A phase I multiple ascending dose (MAD) study of ASC47 in combination with tirzepatide or semaglutide in patients with obesity

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASC 47 (Primary) ; Semaglutide (Primary) ; Tirzepatide (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

  • 12 Aug 2025 According to Ascletis media release, topline data in participants with obesity from the combination study of ASC47 with semaglutide will be presented soon.
  • 17 Nov 2024 New trial record
  • 07 Nov 2024 According to Ascletis media release, detailed clinical data expected to be presented at medical conferences in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top